Immunome, Inc. ((IMNM)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immunome, Inc. is conducting a Phase 1 study titled ‘A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies.’ The study aims to evaluate the safety and effectiveness of IM-1021, an antibody-drug conjugate, in treating individuals with advanced solid and hematologic cancers. This research is significant as it explores new treatment avenues for challenging cancer types.
The intervention being tested is IM-1021, administered intravenously on a 21-day cycle at a starting dose of 2 mg/kg. This biological treatment is designed to target and destroy cancer cells more effectively.
The study employs a sequential intervention model without masking, focusing primarily on treatment. Participants are assigned to a treatment arm where they receive the experimental drug IM-1021.
The study began on February 4, 2025, with the latest update submitted on October 22, 2025. These dates are crucial as they indicate the study’s progression and current status.
This clinical update could influence Immunome’s stock performance positively if the results show promise, as it would enhance the company’s portfolio in the oncology space. Investors should also consider the competitive landscape, as advancements in cancer treatments are highly sought after in the industry.
The study is currently ongoing, and further details can be accessed on the ClinicalTrials portal.